← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $624B	1,989	+12	+0.6%	$199B
2	2 Pfizer PFE $169B	1,743	-4	-0.2%	$130B
3	3 Merck MRK $372B	1,619	-2	-0.1%	$126B
4	4 AbbVie ABBV $510B	1,503	+46	+3%	$72.7B
5	5 Gilead Sciences GILD $197B	1,329	+65	+5%	$139B
6	6 Bristol-Myers Squibb BMY $126B	1,303	0	0%	$61B
7	7 Amgen AMGN $238B	1,223	+37	+3%	$86.9B
8	8 Novartis NVS $288B	875	+27	+3%	$22.2B
9	9 GSK GSK $99.2B	702	-21	-3%	$12.3B
10	10 Regeneron Pharmaceuticals REGN $83.1B	474	+26	+6%	$25.9B
11	11 AstraZeneca AZN $261B	402	-17	-4%	$5.75B
12	12 Jazz Pharmaceuticals JAZZ $14B	326	+21	+7%	$8.57B
13	13 Myriad Genetics MYGN $415M	276	-8	-3%	$3.74B
14	14 Incyte INCY $23.1B	220	+1	+0.5%	$7.86B
15	SGEN 15 DELISTED Seagen Inc. Common Stock SGEN	194	-3	-2%	$4.66B
16	16 Puma Biotechnology PBYI $545M	184	+46	+33%	$6.37B
17	17 Opko Health OPK $1.19B	183	+8	+5%	$636M
18	18 DELISTED Exact Sciences EXAS	175	+19	+12%	$1.43B
19	19 DELISTED Assertio ASRT	159	+29	+22%	$809M
20	20 DELISTED Immunogen Inc IMGN	141	+4	+3%	$795M
21	CLVS 21 DELISTED Clovis Oncology, Inc. CLVS	138	-2	-1%	$1.31B
22	22 DELISTED Merrimack Pharmaceuticals, Inc. MACK	132	+11	+9%	$474M
23	SPPI 23 DELISTED Spectrum Pharmaceuticals Inc SPPI	127	+1	+0.8%	$359M
24	24 Exelixis EXEL $15.6B	125	-11	-8%	$196M
25	25 Geron GERN $790M	123	-5	-4%	$142M